Category: Allergan Inc.Syndicate content

Will Orange County's medtech scene lose its juice without Allergan?

November 20, 2014 by Brian Johnson

Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif., which Allergan's called home for 60 years?

Will Orange County's medtech scene lose its juice without Allergan?

Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014

November 20, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3

InVivo shares soar on spinal cord study update

November 13, 2014 by Val Kennedy

MDT prepares $10B worth of bonds to help fund its $43B acquisition of COV | The week in medtech M&A

November 19, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Report: Medtronic readies $10B bond flotation for Covidien deal; Medtech mergers stayed strong in Q3; Sources: Philips attracts private equity bids for lighting unit; Medtronic, Covidien set timetable for shareholders meetings; Report: Actavis may buy Allergan for at least $60 billion

Report: Medtronic readies $10B bond flotation for Covidien deal

November 17, 2014 by Brad Perriello

Ackman supports Allergan's $66B sale to Actavis

November 18, 2014 by MassDevice

Hedge fund mogul William Ackman abandons the chase for Allergan, throwing his weight behind its $66 billion buyout by Actavis and calling off a shareholders meeting next month over his and Valeant Pharmaceuticals' hostile bid for Allergan.

Ackman supports Allergan's $66B sale to Actavis

Allergan's gains FDA approval for 2 new styles of breast implants | Regulatory news for the week of November 17, 2014

November 18, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: FDA approves 2 new Allergan breast implants; FDA releases October 2014 510(k) clearances; Medicrea wins FDA clearance for patient-specific spinal rod; New electronic formatting requirements in Canada for Class III and IV MDL applications; FDA expects China to OK staff visas after 2-year delay

FDA approves 2 new Allergan breast implants

November 14, 2014 by Val Kennedy

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

November 17, 2014 by Brad Perriello

Allergan agrees to a $66 billion takeover bid from Actavis, thwarting a hostile takeover bid by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital Management.

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

Source: Allergan near $66B buyout to escape Valeant, Ackman

November 17, 2014 by MassDevice

Allergan is close to sealing a deal worth nearly $66 billion with Actavis and giving the slip to a hostile takeover bid from Valeant Pharmaceuticals and William Ackman's Pershing Square hedge fund.

Source: Allergan near $66B buyout to escape Valeant, Ackman

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp